NCT06603155 2025-12-19
Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)
Duke University
Phase NA Withdrawn
Clinical Trials
71 trialsNCT05668949 2025-12-17
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05845307 2025-12-08
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT06086925 2025-07-11
A Window of Opportunity Study of Black Raspberry for Patients With HNSCC
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Withdrawn
NCT05879484 2025-07-10
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT06513884 2025-06-22
A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
Hookipa Biotech GmbH
Phase 2/3 Withdrawn
NCT04595981 2025-04-27
Chemo-embolization for Head and Neck Cancer
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT05608369 2025-04-04
HPV
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05452408 2025-03-18
Antitumor-B KAC PK Study
Medical College of Wisconsin
Phase 1 Withdrawn
NCT05743270 2025-03-11
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Replimune Inc.
Phase 2 Withdrawn
NCT03169764 2025-02-24
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT06084845 2024-07-25
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT06357858 2024-07-03
ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05707702 2024-05-01
Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia
Boston Medical Center
Phase 3 Withdrawn
NCT05412875 2024-04-12
Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT05472506 2024-03-15
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Ikena Oncology
Phase 1 Withdrawn
NCT04892875 2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT03875053 2023-10-04
Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Withdrawn
NCT05359692 2023-09-15
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Incyte Corporation
Phase 2 Withdrawn
NCT04834349 2023-09-13
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04922112 2023-08-02
OSA-HN
University of Colorado, Denver
Phase NA Withdrawn
NCT04987996 2023-06-06
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
Phase 2 Withdrawn
NCT05220748 2023-04-19
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
Rakuten Medical, Inc.
Phase 1 Withdrawn
NCT01332279 2023-04-04
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Fox Chase Cancer Center
Phase 1 Withdrawn
NCT04941365 2022-12-22
SERPENTINE
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Withdrawn
NCT05393635 2022-12-20
DELTA-2
Instil Bio
Phase 1 Withdrawn
NCT04831450 2022-08-04
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Miami
Phase 2 Withdrawn
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn
NCT04849377 2022-07-07
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT05234606 2022-04-12
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Silverback Therapeutics
Phase 1/2 Withdrawn
NCT04266470 2022-03-29
Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region
Wake Forest University Health Sciences
Phase NA Withdrawn
NCT04129320 2022-02-08
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
MacroGenics
Phase 2/3 Withdrawn
NCT05099952 2022-01-12
Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients
Roswell Park Cancer Institute
Phase NA Withdrawn
NCT04607642 2021-10-11
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
BioMimetix JV, LLC
Phase 2 Withdrawn
NCT01967927 2021-08-19
Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy
University of Arkansas
Phase EARLY_PHASE1 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT03673735 2021-05-10
ADHERE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Withdrawn
NCT00492947 2021-04-30
Dendritic
University of Maryland, Baltimore
Phase 1 Withdrawn
NCT04262388 2020-11-17
DOME
University Health Network, Toronto
Phase 2 Withdrawn
NCT04093115 2020-09-03
HNSCC
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Withdrawn
NCT02624999 2020-01-22
Study Comparing AlloVaxâ„¢ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT02686008 2020-01-13
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
Yale University
Phase 1 Withdrawn
NCT03342352 2019-12-20
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
Phase 3 Withdrawn
NCT03575234 2019-08-28
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Emory University
Phase 1 Withdrawn
NCT03611205 2019-08-07
Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT03325465 2019-04-22
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Withdrawn
NCT03114280 2019-04-08
PICH
Centre Antoine Lacassagne
Phase 1/2 Withdrawn
NCT02993991 2017-12-29
PRIMED-001
University Health Network, Toronto
Phase 1 Withdrawn
NCT02211027 2017-09-07
Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA
University of Pittsburgh
Phase 1 Withdrawn